112791-61-4

Basic information

• Product Name: inositol-3,4,5,6-tetrakisphosphate
• Synonyms: inositol-3,4,5,6-tetrakisphosphate;D-Myo-inositol, 3,4,5,6-tetrakis(dihydrogen phosphate)
• CAS NO: 112791-61-4
• Molecular Formula: C₆H₁₆O₁₈P₄
• Molecular Weight: 500.08
• Mol File: 112791-61-4.mol

Chemical Properties

• Boiling Point: 978.1°Cat760mmHg
• Flash Point: 545.3°C
• Appearance: /
• Density: 2.32g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.632
• CAS DataBase Reference: inositol-3,4,5,6-tetrakisphosphate(CAS DataBase Reference)
• NIST Chemistry Reference: inositol-3,4,5,6-tetrakisphosphate(112791-61-4)
• EPA Substance Registry System: inositol-3,4,5,6-tetrakisphosphate(112791-61-4)

Safety Data

• Hazardous Substances Data: 112791-61-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Inositol-3,4,5,6-tetrakisphosphate is used as a pharmaceutical agent for its potential role in modulating cellular signaling pathways. It has been found to play a crucial role in various cellular processes, including calcium signaling, cell growth, and differentiation. Due to its ability to influence these pathways, it holds promise as a therapeutic agent for the treatment of various diseases and disorders.
Used in Research Applications:
Inositol-3,4,5,6-tetrakisphosphate is used as a research tool for studying the role of inositol phosphates in cellular signaling and other biological processes. Its unique structure allows researchers to investigate the mechanisms by which it interacts with proteins and other molecules, providing valuable insights into the regulation of cellular functions.
Used in Drug Development:
Inositol-3,4,5,6-tetrakisphosphate is used as a lead compound in drug development efforts, as its biological activities suggest potential therapeutic applications. Researchers are exploring its potential as a treatment for various conditions, including neurological disorders, cardiovascular diseases, and cancer, by modulating the signaling pathways involved in these diseases.

InChI:InChI=1/C6H16O18P4/c7-1-2(8)4(22-26(12,13)14)6(24-28(18,19)20)5(23-27(15,16)17)3(1)21-25(9,10)11/h1-8H,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20)/t1-,2+,3-,4-,5+,6+/m0/s1

Upstream product

• 143617-31-6 D-1,2-O-(L-1,7,7-trimethyl<2.2.1>bicyclohept-2-ylidene)-myo-inositol 
• 87-89-8 D-myo-inositol 
• 181782-83-2 D-1,2-Di-O-butyryl-myo-inositol 
• 106-51-4 p-benzoquinone 
• 112212-81-4 (+/-)-(1S,2R,3R,4S)-1,4-diacetoxy-2,3-dibromocyclohex-5-ene 
• 69945-44-4 (1RS,2SR,3RS,4RS)-2,3-dibromocyclohex-5-ene-1,4-diol 
• 5273-61-0 (5RS,6RS)-5,6-dibromocyclohex-2-ene-1,4-dione 
• 169529-92-4 (+)-(1R,2S,3S,4R)-2,3-dibromocyclohex-5-ene-1,4-diol 
• 80582-75-8 (1R,2R,3R,4R)-anti-benzene dioxide 
• 222420-83-9 D-myo-3,6-bis-O-(di-O-benzylphospho)-4,5-bis-O-(2-oxo-5,6-benzo-1,3,2-dioxaphosphep-2-yl)inositol 
• 163493-90-1 D-1,2-Di-O-butyryl-myo-inositol 3,4,5,6-tetrakisphosphate 
• 143358-55-8 D-3,4,5,6-tetra-O-(2-oxo-5,6-benzo-1,3,2-dioxaphosphep-2-yl)-1,2-O-(L-1,7,7-trimethyl<2.2.1>bicyclohept-2-ylidene)-myo-inositol 
• 114488-20-9 myo-Inositol 1,5,6-trisphosphate 
• 181782-84-3 D-2,3-Di-O-butyryl-myo-inositol 

Downstream Products

• 1311140-98-3 Inositol 1,5,6-triphosphate 
• 26326-86-3 Ins(1,2,3,4,5)P₅ 
• 114488-20-9 myo-Inositol 1,5,6-trisphosphate 

Relevant articles and documents

Regulation of ins(3456)p4 signalling by a reversible kinase phosphatase and methods and compositions related thereto

Provided is a method of increasing 3,4,5,6-tetrakisphosphate by increasing the activity of inositol 1,3,4,5,6 pentakisphosphate 1-phosphatase, and a method of decreasing 3,4,5,6-tetrakisphosphate by decreasing the activity of inositol 1,3,4,5,6 pentakisph

Diastereoselective synthesis of D- and L-myo-inositol 3,4,5,6- tetrakisphosphates from D-glucose via dihydroxylation of (+)-conduritol B derivatives

Syntheses of D- and L-myo-inositol 3,4,5,6-tetrakisphosphates were achieved via diastereoselective 1,2-addition of vinylcopper reagent with the chiral aldehyde prepared from 1,2,5,6-diisopropylidene-D-glucose, ring-closing metathesis of 1,7-diene with Gru

A Definitive Synthesis of D-myo-Inositol 1,4,5,6-Tetrakisphosphate and Its Enantiomer D-myo-Inositol 3,4,5,6-Tetrakisphosphate from a Novel Butane-2,3-diacetal-Protected Inositol

New and rapid syntheses of the enantiomeric intracellular signalling molecules D-myo-inositol 1,4,5,6-tetrakisphosphate (1a) and D-myo-inositol 3,4,5,6-tetrakisphosphate (1b) are described. The synthetic strategy employs the novel butane-2,3-diacetal-prot

Divergent syntheses of all possible optically active regioisomers of myo-inositol tris- and tetrakisphosphates

Since the discovery of D-myo-inositol 1,4,5-trisphosphate, which plays a pivotal role as a second messenger in transmembrane signaling, the scope of the phosphoinositide-based signaling processes has been continually expanding. However, the clear understanding of the molecular signal transduction mechanisms including the functions of newly found IPn is still lacking. As a continuing effort to our previously reported syntheses of all possible 39 optically inactive regioisomers of myoinositol phosphates (IPn; n = 1-6), we synthesized all possible optically active regioisomers of myo-IP3 and myo-IP4 using chiral IBz3s and IBz2s, respectively. A series of procedures involving CRL-catalyzed enzymatic resolution of racemic 1,2:5,6-di-O-isopropylidene-myo-inositol and base-catalyzed benzoyl migration in tri- and dibenzoyl-isopropylidene-myo-inositol afforded eight enantiomeric pairs of IBz3 and six enantiomeric pairs of IBz2, respectively. Phosphorylation of these intermediates by the phosphitylation and oxidation procedure gave the target products.

Inositol derivatives for inhibiting superoxide anion production

Inositol derivatives, compositions comprising inositol derivatives, and methods for using compositions comprising inositol derivatives as agents for inhibiting superoxide anion production are described. The inositol derivatives are obtainable via conventional organic synthesis. The inositol derivatives inhibit superoxide anion produced by neutrophils and macrophages which cause tissue damage.

Enzyme-assisted total synthesis of the optical antipodes D-myo-inositol 3,4,5-trisphosphate and D-myo-inositol 1,5,6-trisphosphate: Aspects of their structure-activity relationship to biologically active inositol phosphates

Unambiguous total syntheses of both optical antipodes of the enantiomeric pair D-myo-inositol 3,4,5-trisphosphate (Ins(3,4,5)P3) and D- myo-inositol 1,5,6-trisphosphate (Ins(1,5,6)P3) are described. The ring system characteristic of

Membrane-permeant analogues of the putative second messenger myo-inositol 3,4,5,6-tetrakisphosphate

For future investigations of the binding properties of D-myo-inositol 3,4,5,6- and 1,4,5,6-tetrakis-phosphate [D-Ins(3,4,5,6)P4 and D-Ins(1,4,5,6)P4, respectively] to their putative target proteins, a set of analogues with modificati

Lipase-catalyzed regio- and enantioselective esterification of rac-1,2-O-cyclohexylidene-myo-inositol

The hydroxyl group at C-5 in racemic 1,2-O-Cyclohexylidene-myo-inositol (rac-1) was regio- and enantioselectively acylated to give 5-O-acetyl- (2a)- or 5-O-butyryl-2,3-O-cyclohexylidene-myo-inositol (3a), respectively, by treatment of 1 with vinyl acetate

Synthesis of D-myo-inositol 3,4,5,6- and 1,4,5,6-tetrakisphosphate analogues and their membrane-permeant derivatives

A set of D-myo-inositol 3,4,5,6- and 1,4,5,6-tetrakisphosphates [D-Ins(3,4,5,6)P4 and D-Ins(1,4,5,6)P4, respectively] analogues with modifications of the hydroxy groups is synthesized and subsequently converted to the corresponding u